Incorporating biomarkers of frailty and senescence in cancer therapeutic trials

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

As the population ages, oncologists are faced with the quandary of how to efficiently identify frail individuals that may have more difficulty tolerating and recovering from systemic therapy for cancer. Recent advances have been made in recognizing frailty via clinical geriatric assessment of older patients with cancer. These advances appear to allow for better prediction of toxicity than physician-rated performance status. Although the development of these tools is a large step forward in geriatric oncology, we still lack an understanding of how the underlying biologic processes of aging affect tolerance of cancer treatment. Determining specific biologic causes underlying frailty may allow oncologists to become even more adept at identifying patients at risk for excessive toxicity and provide the opportunity to therapeutically target these processes to help improve tolerability and survival outcomes for older patients with cancer. This article provides a background on potential biologic factors that may identify frail individuals at increased risk for toxicity related to cancer treatment. Potential methods to incorporate these factors into cancer therapeutic trials are discussed.

Original languageEnglish (US)
Pages (from-to)722-728
Number of pages7
JournalThe journals of gerontology. Series A, Biological sciences and medical sciences
Volume70
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Biomarkers
Neoplasms
Geriatric Assessment
Therapeutics
Second Primary Neoplasms
Biological Factors
Geriatrics
Physicians
Survival
Population
Oncologists

Keywords

  • Biomarkers of frailty.
  • Frailty
  • Geriatric oncology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9a97da8247eb4e39a7d6b6c60202eb15,
title = "Incorporating biomarkers of frailty and senescence in cancer therapeutic trials",
abstract = "As the population ages, oncologists are faced with the quandary of how to efficiently identify frail individuals that may have more difficulty tolerating and recovering from systemic therapy for cancer. Recent advances have been made in recognizing frailty via clinical geriatric assessment of older patients with cancer. These advances appear to allow for better prediction of toxicity than physician-rated performance status. Although the development of these tools is a large step forward in geriatric oncology, we still lack an understanding of how the underlying biologic processes of aging affect tolerance of cancer treatment. Determining specific biologic causes underlying frailty may allow oncologists to become even more adept at identifying patients at risk for excessive toxicity and provide the opportunity to therapeutically target these processes to help improve tolerability and survival outcomes for older patients with cancer. This article provides a background on potential biologic factors that may identify frail individuals at increased risk for toxicity related to cancer treatment. Potential methods to incorporate these factors into cancer therapeutic trials are discussed.",
keywords = "Biomarkers of frailty., Frailty, Geriatric oncology",
author = "Hubbard, {Joleen M} and Aminah Jatoi",
year = "2015",
month = "6",
day = "1",
doi = "10.1093/gerona/glu046",
language = "English (US)",
volume = "70",
pages = "722--728",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Incorporating biomarkers of frailty and senescence in cancer therapeutic trials

AU - Hubbard, Joleen M

AU - Jatoi, Aminah

PY - 2015/6/1

Y1 - 2015/6/1

N2 - As the population ages, oncologists are faced with the quandary of how to efficiently identify frail individuals that may have more difficulty tolerating and recovering from systemic therapy for cancer. Recent advances have been made in recognizing frailty via clinical geriatric assessment of older patients with cancer. These advances appear to allow for better prediction of toxicity than physician-rated performance status. Although the development of these tools is a large step forward in geriatric oncology, we still lack an understanding of how the underlying biologic processes of aging affect tolerance of cancer treatment. Determining specific biologic causes underlying frailty may allow oncologists to become even more adept at identifying patients at risk for excessive toxicity and provide the opportunity to therapeutically target these processes to help improve tolerability and survival outcomes for older patients with cancer. This article provides a background on potential biologic factors that may identify frail individuals at increased risk for toxicity related to cancer treatment. Potential methods to incorporate these factors into cancer therapeutic trials are discussed.

AB - As the population ages, oncologists are faced with the quandary of how to efficiently identify frail individuals that may have more difficulty tolerating and recovering from systemic therapy for cancer. Recent advances have been made in recognizing frailty via clinical geriatric assessment of older patients with cancer. These advances appear to allow for better prediction of toxicity than physician-rated performance status. Although the development of these tools is a large step forward in geriatric oncology, we still lack an understanding of how the underlying biologic processes of aging affect tolerance of cancer treatment. Determining specific biologic causes underlying frailty may allow oncologists to become even more adept at identifying patients at risk for excessive toxicity and provide the opportunity to therapeutically target these processes to help improve tolerability and survival outcomes for older patients with cancer. This article provides a background on potential biologic factors that may identify frail individuals at increased risk for toxicity related to cancer treatment. Potential methods to incorporate these factors into cancer therapeutic trials are discussed.

KW - Biomarkers of frailty.

KW - Frailty

KW - Geriatric oncology

UR - http://www.scopus.com/inward/record.url?scp=84937603944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937603944&partnerID=8YFLogxK

U2 - 10.1093/gerona/glu046

DO - 10.1093/gerona/glu046

M3 - Article

C2 - 24770389

AN - SCOPUS:84937603944

VL - 70

SP - 722

EP - 728

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 6

ER -